Last reviewed · How we verify
fluocinolone acetonide intraocular implant
Fluocinolone acetonide is a corticosteroid that suppresses inflammatory and immune responses in the eye when delivered directly via intraocular implant.
Fluocinolone acetonide is a corticosteroid that suppresses inflammatory and immune responses in the eye when delivered directly via intraocular implant. Used for Chronic diabetic macular edema, Uveitis affecting the posterior segment of the eye, Macular edema associated with retinal vein occlusion.
At a glance
| Generic name | fluocinolone acetonide intraocular implant |
|---|---|
| Also known as | NDC 24208-416-01 |
| Sponsor | JHSPH Center for Clinical Trials |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
The intraocular implant provides sustained, localized release of fluocinolone acetonide, a potent glucocorticoid, directly to ocular tissues. This reduces inflammation, edema, and immune cell infiltration in the posterior segment of the eye. The implant formulation allows for prolonged therapeutic effect while minimizing systemic exposure.
Approved indications
- Chronic diabetic macular edema
- Uveitis affecting the posterior segment of the eye
- Macular edema associated with retinal vein occlusion
Common side effects
- Cataract formation or progression
- Elevated intraocular pressure / glaucoma
- Endophthalmitis
- Vitreous hemorrhage
- Retinal detachment
Key clinical trials
- The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (PHASE3)
- Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis (PHASE4)
- Multicenter Uveitis Steroid Treatment (MUST) Trial (PHASE4)
- Retisert and Cataract Surgery in Patients With Severe Uveitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: